Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DPJ
|
|||
| Former ID |
DIB007546
|
|||
| Drug Name |
Amezinium
|
|||
| Synonyms |
Amezinium methyl sulfate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypotension [ICD-11: BA20-BA21] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H12N3O+
|
|||
| Canonical SMILES |
COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
|
|||
| InChI |
1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
|
|||
| InChIKey |
VXROHTDSRBRJLN-UHFFFAOYSA-O
|
|||
| CAS Number |
CAS 41658-78-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:145698
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.